Payment overview · 2025
General Payments
$552.45
26 reported records · 11 companies
Healthcare provider profile · identity verified
Dorothy Wilhelm, MD
Allopathic & Osteopathic Physicians|Family Medicine · MONROEVILLE, PA · NPI 1841476124
Verified facts
What the public records show
CMS Open Payments records show Dorothy Wilhelm, MD received $552.45 in general payments during 2025 across 26 reported records.
ABBVIE INC. accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Paxlovid, Prolia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Tudorza Pressair by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.36 | 18.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $104.33 | 18.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.34 | 11.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.47 | 9.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.77 | 8.5% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $45.48 | 8.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.07 | 7.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.64 | 7.2% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.56 | 3.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.61 | 3.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $17.82 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.45 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $104.36 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $84.09 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $84.09 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $46.77 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $45.48 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.42 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.56 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $20.24 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 52 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 17 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 20 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
135 | 34 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
91 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
149 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 826 | 240 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 206 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 624 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 562 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 371 | 109 |
| Valsartan | Valsartan | 356 | 111 |
| Metformin Hcl Er | Metformin Hcl | 338 | 98 |
| Omeprazole | Omeprazole | 260 | 77 |
| Lisinopril | Lisinopril | 226 | 67 |
| Gabapentin | Gabapentin | 208 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 203 | 61 |
| Famotidine | Famotidine | 194 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 41 |
| Sertraline Hcl | Sertraline Hcl | 155 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 154 | 45 |
| Eliquis | Apixaban | 149 | 31 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 144 | 43 |
| Carvedilol | Carvedilol | 140 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 43 |
| Furosemide | Furosemide | 139 | 33 |
| Potassium Chloride | Potassium Chloride | 136 | 39 |
| Synthroid | Levothyroxine Sodium | 135 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 40 |
| Losartan Potassium | Losartan Potassium | 131 | 41 |
| Simvastatin | Simvastatin | 119 | 39 |
| Trazodone Hcl | Trazodone Hcl | 116 | 32 |
| Ozempic | Semaglutide | 115 | 28 |
| Bupropion Hcl Sr | Bupropion Hcl | 101 | 26 |
| Alendronate Sodium | Alendronate Sodium | 91 | 23 |
| Atenolol | Atenolol | 91 | 28 |
| Jardiance | Empagliflozin | 91 | 24 |
| Spironolactone | Spironolactone | 91 | 27 |
| Buspirone Hcl | Buspirone Hcl | 89 | 34 |
| Allopurinol | Allopurinol | 86 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 43 |
| Ezetimibe | Ezetimibe | 82 | 26 |
| Metformin Hcl | Metformin Hcl | 82 | 30 |
| Montelukast Sodium | Montelukast Sodium | 82 | 20 |
| Trulicity | Dulaglutide | 82 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 77 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 25 |
| Glipizide | Glipizide | 75 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 27 |
| Mirtazapine | Mirtazapine | 74 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 50 |
| Bumetanide | Bumetanide | 65 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 54 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 19 |
| Mounjaro | Tirzepatide | 52 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 15 |
| Alprazolam | Alprazolam | 49 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 11 |
| Myrbetriq | Mirabegron | 44 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 44 | 12 |
| Donepezil Hcl | Donepezil Hcl | 43 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 43 | suppressed |
| Cefdinir | Cefdinir | 42 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 11 |
| Bupropion Xl | Bupropion Hcl | 40 | 12 |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Meloxicam | Meloxicam | 38 | 12 |
| Labetalol Hcl | Labetalol Hcl | 37 | suppressed |
| Lorazepam | Lorazepam | 35 | 19 |
| Methylprednisolone | Methylprednisolone | 35 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 33 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 17 |
| Benazepril Hcl | Benazepril Hcl | 32 | 11 |
| Valacyclovir | Valacyclovir Hcl | 32 | 11 |
| Levetiracetam | Levetiracetam | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 28 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 21 |
| Prednisone | Prednisone | 24 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 12 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Prolia | Denosumab | 20 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Trospium Chloride | Trospium Chloride | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Misoprostol | Misoprostol | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Probenecid | Probenecid | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.45 · 26 records | ABBVIE INC. | AREXVY, EVENITY, GEMTESA, INJECTAFER, INSPIRE, JARDIANCE, MOUNJARO, NURTEC ODT, PAXLOVID, PROLIA, QULIPTA, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error